Home  »  Companies   »  Cerevel Therapeutics Holdings Inc. (CERE) Is Now E...

Cerevel Therapeutics Holdings Inc. (CERE) Is Now En Route to Higher Prices

Cerevel Therapeutics Holdings Inc. (NASDAQ: CERE) is -6.57% lower on its value in year-to-date trading and has touched a low of $9.00 and a high of $18.83 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CERE stock was last observed hovering at around $15.26 in the last trading session, with the day’s gains setting it 0.23% off its average median price target of $22.00 for the next 12 months. It is also 32.65% off the consensus price target high of $23.00 offered by 3 analysts, but current levels are 26.24% higher than the price target low of $21.00 for the same period.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Currently trading at $15.49, the stock is 8.93% and 5.58% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.25 million and changing 1.51% at the moment leaves the stock 18.03% off its SMA200. CERE registered a gain of 54.75% in past 6-months. The firm has a 50-day simple moving average (SMA 50) of $14.80 and a 200-day simple moving average (SMA200) of $13.57.

The stock witnessed a 24.42% loss in the last 1 month and extending the period to 3 months gives it a 23.72%, and is 9.62% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.51% over the week and 7.45% over the month.

Distance from 52-week low is 72.11% and -17.76% from its 52-week high.

Cerevel Therapeutics Holdings Inc. (CERE) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Cerevel Therapeutics Holdings Inc. (CERE) is a “Buy”. 3 analysts offering their recommendations for the stock have an average rating of 1.30, where 0 rate it as a Hold and 0 think it is a “Overweight”. 3 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

Cerevel Therapeutics Holdings Inc. is expected to release its quarterly report on 09/01/2021 and quarterly earnings per share for the current quarter are estimated at -$0.41.The EPS is expected to grow by 14.90% this year.

Cerevel Therapeutics Holdings Inc. (CERE) Top Institutional Holders

67 institutions hold shares in Cerevel Therapeutics Holdings Inc. (CERE), with 27.47M shares held by insiders accounting for 21.58% while institutional investors hold 98.54% of the company’s shares. The shares outstanding are 78.58M, and float is at 39.16M with Short Float at 9.24%. Institutions hold 77.27% of the Float.

The top institutional shareholder in the company is Bain Capital Investors, LLC with over 60.63 million shares valued at $1.01 billion. The investor’s holdings represent 47.64% of the CERE Shares outstanding. As of Dec 30, 2020, the second largest holder is Perceptive Advisors Llc with 4.54 million shares valued at $75.34 million to account for 3.57% of the shares outstanding. The other top investors are FMR, LLC which holds 4.31 million shares representing 3.39% and valued at over $71.52 million, while Price (T.Rowe) Associates Inc holds 2.67% of the shares totaling 3.39 million with a market value of $56.24 million.

Cerevel Therapeutics Holdings Inc. (CERE) Insider Activity

A total of 5 insider transactions have happened at Cerevel Therapeutics Holdings Inc. (CERE) in the last six months, with sales accounting for 0 and purchases happening 5 times. The most recent transaction is an insider purchase by BAIN CAPITAL INVESTORS LLC, the company’s 10% Owner. SEC filings show that BAIN CAPITAL INVESTORS LLC bought 332,293 shares of the company’s common stock on Nov 09 at a price of $10.30 per share for a total of $3.42 million. Following the purchase, the insider now owns 60.63 million shares.

Cerevel Therapeutics Holdings Inc. disclosed in a document filed with the SEC on Nov 09 that Koppel Adam (Director) bought a total of 332,293 shares of the company’s common stock. The trade occurred on Nov 09 and was made at $10.30 per share for $3.42 million. Following the transaction, the insider now directly holds 60.63 million shares of the CERE stock.

Still, SEC filings show that on Nov 09, Gordon Christopher R (Director) acquired 332,293 shares at an average price of $10.30 for $3.42 million. The insider now directly holds 60,632,356 shares of Cerevel Therapeutics Holdings Inc. (CERE).

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Related Posts




Download Free eBook For

100% free. stop anytime no spam